Long-term results of children with acute myeloid leukemia: A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891

Frank O. Smith, T. A. Alonzo, R. B. Gerbing, W. G. Woods, R. J. Arceci

Research output: Contribution to journalArticle

Abstract

The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979 and 1995. A total of 1903 eligible children ages birth to 21 years of age were enrolled on CCG 251 (n=485), CCG 213 (n=532) and CCG 2891 (n=886). Follow-up is ongoing, with medians of 7.9, 10.9 and 8.6 years, respectively. These three clinical trials developed dose- and time-intensive induction regimens based upon high-dose cytarabine and daunomycin and randomly assigned patients to allogeneic bone marrow transplantation in first remission if an HLA-matched related donor was identified. Despite dose- and time-intensive induction regimens, remission induction rates remained relatively stable at 77-78%. However, overall survival, event-free survival and disease-free survival (DFS) increased for patients receiving intensive-timing induction therapy in comparison to patients who received standard-timing induction, regardless of the type of postremission therapy. Outcomes were best for patients receiving intensive-timing induction followed by matched related donor allogeneic transplantation with DFS of 65±9% at 6 years. These three clinical trials have established a strong foundation for the development of future studies focusing on further risk group stratification and the development of novel, molecularly-targeted therapies.

Original languageEnglish (US)
Pages (from-to)2054-2062
Number of pages9
JournalLeukemia
Volume19
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Acute Myeloid Leukemia
Disease-Free Survival
Remission Induction
Neoplasms
Homologous Transplantation
Tissue Donors
Clinical Trials
Phase III Clinical Trials
Daunorubicin
Cytarabine
Bone Marrow Transplantation
Therapeutics
Parturition
Survival

Keywords

  • Acute myeloid leukemia
  • Bone marrow transplantation
  • Pediatrics

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Long-term results of children with acute myeloid leukemia : A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. / Smith, Frank O.; Alonzo, T. A.; Gerbing, R. B.; Woods, W. G.; Arceci, R. J.

In: Leukemia, Vol. 19, No. 12, 12.2005, p. 2054-2062.

Research output: Contribution to journalArticle

Smith, Frank O. ; Alonzo, T. A. ; Gerbing, R. B. ; Woods, W. G. ; Arceci, R. J. / Long-term results of children with acute myeloid leukemia : A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. In: Leukemia. 2005 ; Vol. 19, No. 12. pp. 2054-2062.
@article{ffd72d035a1149b6a1f70366ed95d1ed,
title = "Long-term results of children with acute myeloid leukemia: A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891",
abstract = "The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979 and 1995. A total of 1903 eligible children ages birth to 21 years of age were enrolled on CCG 251 (n=485), CCG 213 (n=532) and CCG 2891 (n=886). Follow-up is ongoing, with medians of 7.9, 10.9 and 8.6 years, respectively. These three clinical trials developed dose- and time-intensive induction regimens based upon high-dose cytarabine and daunomycin and randomly assigned patients to allogeneic bone marrow transplantation in first remission if an HLA-matched related donor was identified. Despite dose- and time-intensive induction regimens, remission induction rates remained relatively stable at 77-78{\%}. However, overall survival, event-free survival and disease-free survival (DFS) increased for patients receiving intensive-timing induction therapy in comparison to patients who received standard-timing induction, regardless of the type of postremission therapy. Outcomes were best for patients receiving intensive-timing induction followed by matched related donor allogeneic transplantation with DFS of 65±9{\%} at 6 years. These three clinical trials have established a strong foundation for the development of future studies focusing on further risk group stratification and the development of novel, molecularly-targeted therapies.",
keywords = "Acute myeloid leukemia, Bone marrow transplantation, Pediatrics",
author = "Smith, {Frank O.} and Alonzo, {T. A.} and Gerbing, {R. B.} and Woods, {W. G.} and Arceci, {R. J.}",
year = "2005",
month = "12",
doi = "10.1038/sj.leu.2403925",
language = "English (US)",
volume = "19",
pages = "2054--2062",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Long-term results of children with acute myeloid leukemia

T2 - A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891

AU - Smith, Frank O.

AU - Alonzo, T. A.

AU - Gerbing, R. B.

AU - Woods, W. G.

AU - Arceci, R. J.

PY - 2005/12

Y1 - 2005/12

N2 - The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979 and 1995. A total of 1903 eligible children ages birth to 21 years of age were enrolled on CCG 251 (n=485), CCG 213 (n=532) and CCG 2891 (n=886). Follow-up is ongoing, with medians of 7.9, 10.9 and 8.6 years, respectively. These three clinical trials developed dose- and time-intensive induction regimens based upon high-dose cytarabine and daunomycin and randomly assigned patients to allogeneic bone marrow transplantation in first remission if an HLA-matched related donor was identified. Despite dose- and time-intensive induction regimens, remission induction rates remained relatively stable at 77-78%. However, overall survival, event-free survival and disease-free survival (DFS) increased for patients receiving intensive-timing induction therapy in comparison to patients who received standard-timing induction, regardless of the type of postremission therapy. Outcomes were best for patients receiving intensive-timing induction followed by matched related donor allogeneic transplantation with DFS of 65±9% at 6 years. These three clinical trials have established a strong foundation for the development of future studies focusing on further risk group stratification and the development of novel, molecularly-targeted therapies.

AB - The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979 and 1995. A total of 1903 eligible children ages birth to 21 years of age were enrolled on CCG 251 (n=485), CCG 213 (n=532) and CCG 2891 (n=886). Follow-up is ongoing, with medians of 7.9, 10.9 and 8.6 years, respectively. These three clinical trials developed dose- and time-intensive induction regimens based upon high-dose cytarabine and daunomycin and randomly assigned patients to allogeneic bone marrow transplantation in first remission if an HLA-matched related donor was identified. Despite dose- and time-intensive induction regimens, remission induction rates remained relatively stable at 77-78%. However, overall survival, event-free survival and disease-free survival (DFS) increased for patients receiving intensive-timing induction therapy in comparison to patients who received standard-timing induction, regardless of the type of postremission therapy. Outcomes were best for patients receiving intensive-timing induction followed by matched related donor allogeneic transplantation with DFS of 65±9% at 6 years. These three clinical trials have established a strong foundation for the development of future studies focusing on further risk group stratification and the development of novel, molecularly-targeted therapies.

KW - Acute myeloid leukemia

KW - Bone marrow transplantation

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=28544445097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544445097&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403925

DO - 10.1038/sj.leu.2403925

M3 - Article

C2 - 16136168

AN - SCOPUS:28544445097

VL - 19

SP - 2054

EP - 2062

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -